Generic Pharmaceutical Savings Reach $217 Billion in 2012

Published Online: Wednesday, December 18, 2013
Follow Pharmacy_Times:

WASHINGTON, DC (December 18, 2013) — The Generic Pharmaceutical Association (GPhA) today released the fifth annual report, Generic Drug Savings in the U.S., showing that the use of generic medicines resulted in $217 billion in savings to the U.S. health care system in 2012 and $1.2 trillion over the last 10 years (2003-2012). For the first time, this year’s report features a special section on retail savings, confirming the savings that generic medicines deliver to millions of people.

“The generic pharmaceutical industry continues to generate unprecedented savings for the U.S. health system,” said Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association (GPhA), which released the report. “As more Americans seek out affordable treatment options, generic medicines remain one of the few tried and true ways that patients, payers, the business community and others can find some relief from soaring health costs.”

For the first time, this report breaks out the savings for each payer type (i.e., out-of-pocket, insurers, Medicaid, other third-party payers) at the retail level. Retail sales represent approximately 76 percent of total savings from generics. In 2012 alone, savings for the retail markets totaled $171 billion. Interestingly, generics have saved out-of-pocket cash payers $78 billion over the past 10 years – these typically are the uninsured and poorer customers. All data were compiled by IMS Health on behalf of GPhA.

Select findings from the 2013 Generic Drug Savings Report:

Segment Savings from Generics
Retail market overall savings $931 Billion over 10 years
Commercial third-party payers (insurance companies, employee health plans) $552 billion over the past 10 years
Medicare Part D or other federal benefit enrollee savings $301 billion over 10 years
Seniors enrolled in Medicare Part D $189 billion since Part D program began in 2006
Medicaid beneficiaries who get prescriptions from retail outlets $96 billion over 10 years
Patients/Customers paying out-of-pocket (typically uninusred or underinsured) $78 billion over 10 years

“From policymakers to patients, any efforts to curtail health spending must capitalize on the savings from safe, affordable generic medicines. In a time when cutting costs is everyone’s priority, generics continue to put more treatments within reach for so many people,” said Neas. “Embracing policy that encourages access to generic medicines goes hand in hand with savings.”

Click here for the full report.
Related Articles
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
Today Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) introduced H.R. 5815, The Generic Drug Pricing Fairness Act, which creates greater transparency in how pharmacy benefit managers reimburse pharmacies for generic prescription drugs under Medicare Part D, and the Federal Employees Health Benefits Program. The National Community Pharmacists Association endorsed the bill, which goes further than legislation the same two Congressmen introduced earlier year that has the same remedies, but only applied to Medicare Part D.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
The Generic Pharmaceutical Association announced that it has named Terry Bazyluk as Vice President for Communications, effective December 1, 2014.
Latest Issues